A Phase 2/3 interventional study of folinic acid in Down Syndrome, sponsored by Institut Jerome Lejeune. Completed at 1 site in France. Open to participants aged 3 Months to 30 Months. Per ClinicalTrials.gov, last updated 2009-12-17.
Sponsored by Institut Jerome Lejeune · Phase 2/3, Interventional, and Treatment
The purpose of this study is to determine whether folinic acid can improve developmental quotient of young Down syndrome patients, given that these present signs of folate deficiency which are known to cause reversible neurological, psychiatric and cognitive disorders.
432 studies on the registry are indexed under Down Syndrome; 100 are open to participants now.
This study's enrollment of 120 is above the median of 36 across 283 interventional studies indexed under Down Syndrome.
Browse Down Syndrome studies →Institut Jerome Lejeune is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Score on a psychomotor development scale after a 6 and 12 months treatment
This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Jerome Lejeune